RS59394B1 - Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze - Google Patents
Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklazeInfo
- Publication number
- RS59394B1 RS59394B1 RSP20191306A RS59394B1 RS 59394 B1 RS59394 B1 RS 59394B1 RS P20191306 A RSP20191306 A RS P20191306A RS 59394 B1 RS59394 B1 RS 59394B1
- Authority
- RS
- Serbia
- Prior art keywords
- guanylate cyclase
- soluble guanylate
- cyclase activators
- pyrazoles
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261697899P | 2012-09-07 | 2012-09-07 | |
| EP13762666.9A EP2892891B1 (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| PCT/US2013/057826 WO2014039434A1 (en) | 2012-09-07 | 2013-09-03 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59394B1 true RS59394B1 (sr) | 2019-11-29 |
Family
ID=49170904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP20191306 RS59394B1 (sr) | 2012-09-07 | 2013-09-03 | Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8906904B2 (sr) |
| EP (1) | EP2892891B1 (sr) |
| JP (1) | JP5970134B2 (sr) |
| KR (1) | KR101692707B1 (sr) |
| CN (1) | CN104619695B (sr) |
| AP (1) | AP2015008231A0 (sr) |
| AR (1) | AR092869A1 (sr) |
| AU (1) | AU2013312931B2 (sr) |
| BR (1) | BR112015004529B1 (sr) |
| CA (1) | CA2880494C (sr) |
| CL (2) | CL2015000255A1 (sr) |
| CY (1) | CY1122610T1 (sr) |
| DK (1) | DK2892891T3 (sr) |
| EA (1) | EA027244B1 (sr) |
| EC (1) | ECSP15012804A (sr) |
| ES (1) | ES2748798T3 (sr) |
| GE (1) | GEP20176631B (sr) |
| HK (1) | HK1210164A1 (sr) |
| HR (1) | HRP20191755T1 (sr) |
| HU (1) | HUE046996T2 (sr) |
| IL (1) | IL236987A (sr) |
| LT (1) | LT2892891T (sr) |
| MA (1) | MA37891B1 (sr) |
| MD (1) | MD4425C1 (sr) |
| MX (1) | MX338887B (sr) |
| NZ (1) | NZ703989A (sr) |
| PE (1) | PE20151001A1 (sr) |
| PH (1) | PH12015500457A1 (sr) |
| PL (1) | PL2892891T3 (sr) |
| PT (1) | PT2892891T (sr) |
| RS (1) | RS59394B1 (sr) |
| SG (2) | SG10201510668UA (sr) |
| SI (1) | SI2892891T1 (sr) |
| TN (1) | TN2015000054A1 (sr) |
| TW (1) | TWI586661B (sr) |
| UA (1) | UA115881C2 (sr) |
| UY (1) | UY35012A (sr) |
| WO (1) | WO2014039434A1 (sr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20176631B (en) * | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| ES2784477T3 (es) | 2014-07-22 | 2020-09-28 | Boehringer Ingelheim Int | Acidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble |
| WO2017103888A1 (en) | 2015-12-18 | 2017-06-22 | Novartis Ag | Indane derivatives and the use thereof as soluble guanylate cyclase activators |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| WO2019211081A1 (en) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| TW202015676A (zh) | 2018-05-15 | 2020-05-01 | 德商拜耳廠股份有限公司 | 經1,3-噻唑-2-基取代之苯甲醯胺用於治療與神經纖維敏化作用相關疾病之用途 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| EP3820470A1 (en) * | 2018-07-12 | 2021-05-19 | Boehringer Ingelheim International GmbH | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| CN112079712B (zh) * | 2020-09-18 | 2022-12-13 | 江苏美迪克化学品有限公司 | 一种对乙烯基水杨酸的制备方法 |
| GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| TW202402274A (zh) | 2022-03-21 | 2024-01-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療門脈高壓之可溶性鳥苷酸環化酶活化劑 |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| CA2428989A1 (en) | 2000-11-22 | 2002-05-30 | Visx Incorporated | Temperature actuated positioning device for non-linear optical elements |
| GB0212785D0 (en) * | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
| EP1572693A1 (en) | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds |
| CA2615426A1 (en) | 2005-07-18 | 2007-01-25 | Bayer Healthcare Ag | Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| US20100210643A1 (en) | 2007-05-12 | 2010-08-19 | Bayer Schering Pharma Aktiengesellschaft | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS |
| WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
| MX2010003071A (es) * | 2007-10-05 | 2010-04-01 | Sanofi Aventis Deutschland | Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor. |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| TW200938529A (en) * | 2007-12-03 | 2009-09-16 | Smithkline Beecham Corp | Compounds |
| JP5432890B2 (ja) * | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| WO2010015653A1 (en) | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Pyrimidine derivatives as activators of soluble guanylate cyclase |
| WO2010015652A2 (en) * | 2008-08-07 | 2010-02-11 | Smithkline Beecham Corporation | Thiazole compounds as activators of soluble guanylate cyclase |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| JP5780430B2 (ja) | 2009-01-17 | 2015-09-16 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤 |
| JP5411300B2 (ja) | 2009-02-26 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | 可溶性グアニレートシクラーゼ活性化剤 |
| ES2548394T3 (es) * | 2010-02-05 | 2015-10-16 | Adverio Pharma Gmbh | Estimuladores de la GCs o activadores de la GCs solos y en combinación con inhibidores de la PDE5 para el tratamiento de la fibrosis quística |
| WO2011095553A1 (en) | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| ME02207B (me) * | 2010-05-26 | 2016-02-20 | Adverio Pharma Gmbh | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) |
| US20130158028A1 (en) | 2010-06-25 | 2013-06-20 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| US8895583B2 (en) | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| WO2013025425A1 (en) | 2011-08-12 | 2013-02-21 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2594270A3 (en) | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
| GEP20176631B (en) * | 2012-09-07 | 2017-02-27 | Boehringer Ingelheim Int | Alkoxy pyrazoles as soluble guanylate cyclase activators |
-
2013
- 2013-09-03 GE GEAP201313783A patent/GEP20176631B/en unknown
- 2013-09-03 BR BR112015004529-4A patent/BR112015004529B1/pt active IP Right Grant
- 2013-09-03 SI SI201331583T patent/SI2892891T1/sl unknown
- 2013-09-03 LT LTEP13762666.9T patent/LT2892891T/lt unknown
- 2013-09-03 KR KR1020157005961A patent/KR101692707B1/ko active IP Right Grant
- 2013-09-03 AP AP2015008231A patent/AP2015008231A0/xx unknown
- 2013-09-03 PE PE2015000295A patent/PE20151001A1/es active IP Right Grant
- 2013-09-03 SG SG10201510668UA patent/SG10201510668UA/en unknown
- 2013-09-03 MD MDA20150019A patent/MD4425C1/ro active IP Right Grant
- 2013-09-03 NZ NZ703989A patent/NZ703989A/en unknown
- 2013-09-03 UA UAA201503030A patent/UA115881C2/uk unknown
- 2013-09-03 MA MA37891A patent/MA37891B1/fr unknown
- 2013-09-03 EP EP13762666.9A patent/EP2892891B1/en active Active
- 2013-09-03 WO PCT/US2013/057826 patent/WO2014039434A1/en active Application Filing
- 2013-09-03 EA EA201500298A patent/EA027244B1/ru not_active IP Right Cessation
- 2013-09-03 CN CN201380046266.3A patent/CN104619695B/zh active Active
- 2013-09-03 HU HUE13762666A patent/HUE046996T2/hu unknown
- 2013-09-03 DK DK13762666.9T patent/DK2892891T3/da active
- 2013-09-03 PT PT137626669T patent/PT2892891T/pt unknown
- 2013-09-03 RS RSP20191306 patent/RS59394B1/sr unknown
- 2013-09-03 ES ES13762666T patent/ES2748798T3/es active Active
- 2013-09-03 US US14/016,452 patent/US8906904B2/en not_active Ceased
- 2013-09-03 CA CA2880494A patent/CA2880494C/en active Active
- 2013-09-03 JP JP2015531142A patent/JP5970134B2/ja active Active
- 2013-09-03 PL PL13762666T patent/PL2892891T3/pl unknown
- 2013-09-03 SG SG11201500861QA patent/SG11201500861QA/en unknown
- 2013-09-03 AU AU2013312931A patent/AU2013312931B2/en active Active
- 2013-09-03 MX MX2015002807A patent/MX338887B/es active IP Right Grant
- 2013-09-06 UY UY0001035012A patent/UY35012A/es active IP Right Grant
- 2013-09-06 AR ARP130103197A patent/AR092869A1/es active IP Right Grant
- 2013-09-06 TW TW102132286A patent/TWI586661B/zh active
-
2015
- 2015-01-29 IL IL236987A patent/IL236987A/en active IP Right Grant
- 2015-02-03 CL CL2015000255A patent/CL2015000255A1/es unknown
- 2015-02-18 TN TNP2015000054A patent/TN2015000054A1/fr unknown
- 2015-03-03 PH PH12015500457A patent/PH12015500457A1/en unknown
- 2015-03-06 CL CL2015000562A patent/CL2015000562A1/es unknown
- 2015-04-02 EC ECIEPI201512804A patent/ECSP15012804A/es unknown
- 2015-11-06 HK HK15110980.4A patent/HK1210164A1/xx unknown
-
2016
- 2016-10-31 US US15/338,605 patent/USRE46886E1/en active Active
-
2019
- 2019-09-26 HR HRP20191755TT patent/HRP20191755T1/hr unknown
- 2019-10-22 CY CY20191101099T patent/CY1122610T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1210164A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| IL223259A0 (en) | Soluble guanylate cyclase activators | |
| EP2632551A4 (en) | ACTIVATORS OF THE SOLUBLE GUANYLATE CYCLASE | |
| EP2549875A4 (en) | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | |
| EP3079700A4 (en) | Soluble guanylate cyclase activators | |
| EP3079701A4 (en) | Soluble guanylate cyclase activators | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| HK1207376A1 (en) | Arylethynyl derivatives | |
| HK1202544A1 (zh) | 芳基乙炔基衍生物 | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| GB201219296D0 (en) | Pyrazole derivatives | |
| GB201219289D0 (en) | Pyrazole derivatives | |
| GB201218245D0 (en) | Pyrazole derivatives | |
| ZA201103204B (en) | Phenylpyrazole derivatives |